The U.S. drugmaker Johnson & Johnson has announced it has a one-dose version of a COVID-19 vaccine that has proven to be effective against severe symptoms. However, not as effective as the already available two-dose versions produced by the company’s competitors.
Trials show the one-dose vaccine is, on average, 66 percent effective at preventing moderate to severe illness, and about 85 percent effective against the more serious symptoms of COVID-19. This, compared to both Pfizer and Moderna, which have two-dose vaccines that have an overall 95 percent effectiveness.
“Our goal all along has been to create a simple, effective solution for the largest number of people possible, and to have maximum impact to help end the pandemic,” said Alex Gorsky, Chairman, Board of Directors and Chief Executive Officer, Johnson & Johnson. “We’re proud to have reached this critical milestone and our commitment to address this global health crisis continues with urgency for everyone, everywhere.”
Health officials have long looked for a one-dose solution to help shore up global stalling vaccine production, and to help alleviate some of the logistical hurdles in making sure everyone comes back for their second shot. It must be decided if the single-shot vaccine is worth the reduction in efficacy.
The drugmaker has vowed to produce 100 million doses of its one-shot vaccine for the United States by June of this year. Canadian officials had previously inked a deal with Johnson & Johnson to supply 38 million doses of its vaccine, when available. There is as yet no schedule for delivery.